Policy Lab

This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin Lymphoma (HL) in patients with significant comorbidities who are ineligible to be treated with standard chemotherapy

This trial will study brentuximab vedotin (BV) (Part E), to find out whether it is an effective treatment for Hodgkin Lymphoma. Patients in this study will have other conditions that make them unable to receive standard chemotherapy treatment.

Trial ID: NCT01716806

Trial Details

We want to learn if the study drug brentuximab vedotin (BV) can be used to treat patients who have Hodgkin Lymphoma, have not received any prior treatments and are not able to receive multiagent chemotherapy. BV is designed to find and stick to certain cells and prevent the cancer from growing. In this part of the study, Part E, Seagen wants to find out if BV alone is safe, effective, and how well it is tolerated.

This is an open-label study. That means both you and the study team will know which study drug(s) you are getting.


Estimated Enrollment

50 Participants



Eligibility Criteria

Participants must:
  • Be 18 years of age or older (Adult, Older Adult)
  • Have Hodgkin Lymphoma with measurable disease on imaging
  • Be unsuitable or unfit for initial standard combination chemotherapy
Participants must not:
  • Have had a severe viral bacterial or fungal infection within 2 weeks of the first dose of brentuximab vedotin
  • Have had another cancer within 1 year
  • Have cancer that has spread to your brain or spinal cord
  • Be receiving treatment with another experimental or clinical trial drug at the same time

What Will Happen in This Study

What’s Involved

If you choose to take part in this study, we’ll do tests to see if you can be in the study. If you can be in the study and choose to take part, we’ll do tests to see if the study drug can affect your cancer. If your cancer stays the same or gets better, and you don’t have any serious problems, you can keep getting the study drug for up to 16 cycles.

We will take blood samples for safety and research tests and to check on your disease. These are extra blood samples just for the study. You will also get blood drawn for your normal medical care.

The study doctor will review your medical history and complete one or two tools to determine if you are not able to receive standard chemotherapy treatment.

You will need to travel to one of the study clinics taking part in this clinical trial.

Sites are located in the cities/states identified with the red pin:

Frequently Asked Questions (FAQs)